ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2024
Zinzino group revenue increased with a total of 15%, compared with the previous year.
The revenue in January for Zinzino's sales markets increased by 17% and amounted to SEK 140.2 (120.3) million. Faun Pharma's external sales decreased by 11% and amounted to SEK 8.1 (9.1) million. Overall, the Group increased revenues by 15% to SEK 148.3 (129.4) million compared with the previous year.
Revenues were distributed as follows:
| Regions, mSEK | 24-Jan | 23-Jan | Change |
| The Nordics | 22.6 | 23.4 | -3% |
| Central Europe | 41,0 | 28.5 | 44% |
| East Europe | 31.8 | 32.8 | -3% |
| South & West Europe | 21.8 | 15.9 | 37% |
| The Baltics | 8,0 | 7.4 | 8% |
| North America | 10.1 | 6.3 | 60% |
| Asia-Pacific | 3.9 | 4.6 | -15% |
| Africa | 1,0 | 1.4 | -29% |
| Zinzino | 140.2 | 120.3 | 17% |
| Faun Pharma | 8.1 | 9.1 | -11% |
| Zinzino Group | 148.3 | 129.4 | 15% |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge: marketing@zinzino.com
Certified Adviser: Carnegie Investment Bank AB (publ)
Zinzino is a global direct sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their scientifically proven n utritional supplements are available on more than 100 markets across the world. Zinzino owns the Swiss, biotech skincare brand HANZZ+HEIDII, as well as the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Europe, Asia, the US and Australia.